NAGIOS: RODERIC FUNCIONANDO

Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: a pilot study comparing fibrin rich in growth factors and teriparatide

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: a pilot study comparing fibrin rich in growth factors and teriparatide

Mostra el registre parcial de l'element

dc.contributor.author Pelaz, A. es
dc.contributor.author Junquera Gutiérrez, Luis Manuel es
dc.contributor.author Gallego, Lorena es
dc.contributor.author García-Consuegra, L. es
dc.contributor.author Junquera, Sonsoles es
dc.contributor.author Gómez Alonso, Carlos es
dc.date.accessioned 2015-01-08T12:31:05Z
dc.date.available 2015-01-08T12:31:05Z
dc.date.issued 2014 es
dc.identifier.citation Pelaz, A. ; Junquera Gutiérrez, Luis Manuel ; Gallego, Lorena ; García-Consuegra, L. ; Junquera, Sonsoles ; Gómez Alonso, Carlos. Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: a pilot study comparing fibrin rich in growth factors and teriparatide. En: Medicina oral, patología oral y cirugía bucal. Ed inglesa, 2014, Vol. 19, No. 4: 320-326 es
dc.identifier.uri http://hdl.handle.net/10550/41132
dc.description.abstract Objectives: The aim of this study is to describe and compare the evolution of recurrent bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients treated with plasma rich in growth factors or teriparatide. Material and Methods: Two different types of treatments were applied in patients diagnosed of recurrent BRONJ in a referral hospital for 1.100.000 inhabitants. In the group A, plasma rich in growth factors was applied dur - ing the surgery. In the group B, the treatment consisted in the subcutaneous administration of teriparatide. All the cases of BRONJ should meet the following conditions: recurrent BRONJ, impossibility of surgery in stage 3 Ruggiero classification and absence of diagnosed neoplastic disease. Clinical and radiographic evolution of the patients from both groups was observed. Results: Nine patients were included, 5 in group A and 4 in group B. All the patients were women on oral bis- phosphonate therapy for primary osteoporosis (5 patients) or osteoporosis-related to the use of corticosteroids (4 patients). Alendronate was the most common oral bisphosphonate associated with BRONJ in our study (four patients in group A and two in group B). The mean age was 72,8 years in the group A and 73,5 years in the group B. All the patients from group A showed a complete resolution of their BRONJ. Only one patient in the group B showed the same evolution. Conclusions: In our series, the plasma rich in growth factors showed better results than the teriparatide in the treatment of recurrent BRONJ. en_US
dc.subject Odontología es
dc.subject Ciencias de la salud es
dc.title Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: a pilot study comparing fibrin rich in growth factors and teriparatide es
dc.type journal article es_ES
dc.subject.unesco UNESCO::CIENCIAS MÉDICAS es
dc.type.hasVersion VoR es_ES
dc.identifier.url http://www.medicinaoral.com/pubmed/medoralv19_i4_p320.pdf es

Visualització       (780.6Kb)

Aquest element apareix en la col·lecció o col·leccions següent(s)

Mostra el registre parcial de l'element

Cerca a RODERIC

Cerca avançada

Visualitza

Estadístiques